A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 06 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2013 Planned end date changed from 1 Jan 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 18 Apr 2012 Planned End Date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.